Nuvation Bio [NUVB] vs Capricor [CAPR] Detailed Stock Comparison

Nuvation Bio Inc.

NYSE
Loading...

Capricor Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Nuvation Bio Inc. wins in 6 metrics, Capricor Therapeutics Inc. wins in 9 metrics, with 0 ties. Capricor Therapeutics Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Nuvation Bio Inc. Capricor Therapeutics Inc. Better
P/E Ratio (TTM) N/A -15.61 N/A
Price-to-Book Ratio 5.81 6.62 Nuvation Bio Inc.
Debt-to-Equity Ratio 21.90 4.75 Capricor Therapeutics Inc.
PEG Ratio -35.31 -0.05 Capricor Therapeutics Inc.
EV/EBITDA -6.23 -16.23 Nuvation Bio Inc.
Profit Margin (TTM) 85.22% 0.00% Nuvation Bio Inc.
Operating Margin (TTM) -81.30% 0.00% Capricor Therapeutics Inc.
Return on Equity -53.18% -46.56% Capricor Therapeutics Inc.
Return on Assets (TTM) -23.46% -25.68% Nuvation Bio Inc.
Free Cash Flow (TTM) $-181.78M $-81.54M Capricor Therapeutics Inc.
1-Year Return 125.47% 202.93% Capricor Therapeutics Inc.
Price-to-Sales Ratio (TTM) 28.30 N/A N/A
Enterprise Value $1.32B $1.72B Capricor Therapeutics Inc.
EV/Revenue Ratio 20.94 N/A N/A
Gross Profit Margin (TTM) 96.94% N/A N/A
Revenue per Share (TTM) $0 $0 Nuvation Bio Inc.
Earnings per Share (Diluted) $-0.60 $-2.26 Nuvation Bio Inc.
Beta (Stock Volatility) 1.61 0.48 Capricor Therapeutics Inc.
Short % of Float 23.23% 19.17% Capricor Therapeutics Inc.

Nuvation Bio Inc. vs Capricor Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

NUVB
CAPR

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Nuvation Bio Inc.-3.67%-0.42%7.03%8.26%-43.61%-44.99%
Capricor Therapeutics Inc.1.10%-5.15%-17.49%6.97%-7.74%-2.37%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Nuvation Bio Inc.125.47%179.53%-60.98%-51.96%-51.96%-51.96%
Capricor Therapeutics Inc.202.93%558.46%676.17%-7.24%-90.64%-97.72%

Performance & Financial Health Analysis: Nuvation Bio Inc. vs Capricor Therapeutics Inc.

MetricNUVBCAPR
Market Information
Market Cap i$1.75B$2.04B
Market Cap CategorySmall capMid cap
10 Day Avg. Volume i2,882,977987,380
90 Day Avg. Volume i3,312,7821,234,213
Last Close$4.72$27.64
52 Week Range$1.57 - $9.75$4.30 - $40.37
% from 52W High-51.59%-31.53%
All-Time High$15.23 (May 24, 2021)$3,500.00 (Oct 22, 2007)
% from All-Time High-69.01%-99.21%
Growth Metrics
Quarterly Revenue Growth6.33%N/A
Quarterly Earnings Growth6.33%-1.00%
Financial Health
Profit Margin (TTM) i0.85%0.00%
Operating Margin (TTM) i-0.81%0.00%
Return on Equity (TTM) i-0.53%-0.47%
Debt to Equity (MRQ) i21.904.75
Cash & Liquidity
Book Value per Share (MRQ)$0.88$5.33
Cash per Share (MRQ)$1.52$5.53
Operating Cash Flow (TTM) i$-173,427,008$-69,811,264
Levered Free Cash Flow (TTM) i$-115,776,248$-39,600,748
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Nuvation Bio Inc. vs Capricor Therapeutics Inc.

MetricNUVB (Apr 24, 2026)CAPR (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/A-15.61
Forward P/E i-35.31-56.73
PEG Ratio i-35.31-0.05
Price to Sales (TTM) i28.30N/A
Price to Book (MRQ) i5.816.62
Market Capitalization
Market Capitalization i$1.75B$2.04B
Enterprise Value i$1.32B$1.72B
Enterprise Value Metrics
Enterprise to Revenue i20.94N/A
Enterprise to EBITDA i-6.23-16.23
Risk & Other Metrics
Beta i1.610.48
Book Value per Share (MRQ) i$0.88$5.33

Financial Statements Comparison: Nuvation Bio Inc. vs Capricor Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNUVB (2025)CAPR (2025)
Revenue/Sales i62.90M0
Cost of Goods Sold i9.30MN/A
COGS % of Revenue i14.8%-
Gross Profit i53.60MN/A
Gross Margin i85.2%-
Research & Development i115.11M84.45M
Operating Income (EBIT) i-213.06M-108.14M
Operating Margin i-338.7%-
EBITDA i-188.37M-106.21M
EBITDA Margin i-299.5%-
Pre-Tax Income i-204.63M-105.04M
Pre-Tax Income % of Revenue i-325.3%-
Income Tax i01,600
Income Tax % of Revenue i0.0%-
Net Income (Profit) i-204.63M-105.04M
Profit Margin i-325.3%-

Balance Sheet & Liquidity Metrics

MetricNUVB (2025)CAPR (2025)
Cash & Equivalents i164.09M287.85M
Total Current Assets i571.52M322.94M
Total Current Assets % of Revenue i908.6%-
Total Current Liabilities i82.23M35.84M
Total Current Liabilities % of Revenue i130.7%-
Long-Term Debt i49.75M14.32M
Long-Term Debt % of Revenue i79.1%-
Total Shareholders Equity i305.72M305.79M
Retained Earnings i-1.12B-304.88M
Retained Earnings % of Revenue i-1,773.2%-
Property, Plant & Equipment i3.92M22.27M

Cash Flow Statement Comparison

MetricNUVB (2025)CAPR (2025)
Operating Cash Flow i-175.98M-71.86M
Operating Cash Flow % of Revenue i-279.8%-
Capital Expenditures i-354,000-11.72M
Free Cash Flow i-181.78M-81.54M
FCF Margin i-289.0%-
Debt Repayment i-11.90MN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricNUVBCAPR
Shares Short i48.73M10.04M
Short Ratio i9.627.73
Short % of Float i23.23%19.17%
Shares Outstanding i346.50M57.37M
Float Shares i237.04M48.61M
% Held by Insiders i18.67%9.47%
% Held by Institutions i62.24%53.91%
% Held by Public i19.09%36.62%

Dividend Analysis & Yield Comparison: Nuvation Bio Inc. vs Capricor Therapeutics Inc.

MetricNUVBCAPR
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A